In vivo cardiac myosin binding protein C gene transfer rescues myofilament contractile dysfiunction in cardiac myosin binding protein C null mice

Circulation: Heart Failure

Volumn 5, Issue 5, 2012, Pages 635-644

  Merkulov, Sergei ^a   Chen, Xiaoqin ^a   Chandler, Margaret P ^a   Stelzer, Julian E ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiomyopathy; Echocardiography; Gene therapy; Myocardial contraction

Indexed keywords

CARDIAC MYOSIN BINDING PROTEIN C; MYOSIN BINDING PROTEIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE THERAPY; GENE TRANSFER; HEART LEFT VENTRICLE WALL; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SARCOMERE; WILD TYPE;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; KINETICS; MALE; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHORYLATION; RECOMBINANT PROTEINS; RECOVERY OF FUNCTION; VENTRICULAR FUNCTION, LEFT;

EID: 84868644562     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.112.968941     Document Type: Article

References (37)

1. Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med. 2011;364:1643-1656.
2. Morita H, Nagai R, Seidman JG, Seidman CE. Sarcomere gene mutations in hypertrophy and heart failure. J Cardiovasc Transl Res. 2010;3:297-303.
3. Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. 2011;108:751-764.
4. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CAR-DIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785-789.
5. Seidman CE, Seidman JG. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. Circ Res. 2011;108:743-750.
6. van Dijk SJ, Dooijes D, dos Remedios C, Michels M, Lamers JM, Wine-grad S, Schlossarek S, Carrier L, ten Cate FJ, Stienen GJ, van der Velden J. Cardiac myosin-binding protein C mutations and hypertrophic cardio-myopathy: haploinsufficiency, deranged phosphorylation, and cardio-myocyte dysfiunction. Circulation. 2009;119:1473-1483.
7. Marston S, Copeland O, Jacques A, Livesey K, Tsang V, McKenna WJ, Jalilzadeh S, Carballo S, Redwood C, Watkins H. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardio-myopathy through haploinsufficiency. Circ Res. 2009;105:219-222.
8. Harris SP, Bartley CR, Hacker TA, McDonald KS, Douglas PS, Greaser ML, Powers PA, Moss RL. Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ Res. 2002;90:594-601. (Pubitemid 34640910)
9. Palmer BM, Georgakopoulos D, Janssen PM, Wang Y, Alpert NR, Belardi DF, Harris SP, Moss RL, Burgon PG, Seidman CE, Seid-man JG, Maughan DW, Kass DA. Role of cardiac myosin binding protein C in sustaining left ventricular systolic stiffening. Circ Res. 2004;94:1249-1255. (Pubitemid 38656412)
10. Nagayama T, Takimoto E, Sadayappan S, Mudd JO, Seidman JG, Rob-bins J, Kass DA. Control of in vivo left ventricular [correction] contraction/relaxation kinetics by myosin binding protein C: protein kinase A phosphorylation dependent and independent regulation. Circulation. 2007;116:2399-2408. (Pubitemid 350145075)
11. Tong CW, Stelzer JE, Greaser ML, Powers PA, Moss RL. Acceleration of crossbridge kinetics by protein kinase A phosphorylation of cardiac myosin binding protein C modulates cardiac function. Circ Res. 2008;103:974-982.
12. Carrier L, Knöll R, Vignier N, Keller DI, Bausero P, Prudhon B, Isnard R, Ambroisine ML, Fiszman M, Ross J Jr, Schwartz K, Chien KR. Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. Cardio-vasc Res. 2004;63:293-304. (Pubitemid 38900843)
13. Desjardins CL, Chen Y, Coulton AT, Hoit BD, Yu X, Stelzer JE. Cardiac myosin binding protein C insufficiency leads to early onset of mechanical dysfiunction. Circ Cardiovasc Imaging. 2012;5:127-136.
14. Stelzer JE, Patel JR, Walker JW, Moss RL. Differential roles of cardiac myosin-binding protein C and cardiac troponin I in the myof-brillar force responses to protein kinase A phosphorylation. Circ Res. 2007;101:503-511. (Pubitemid 47347881)
15. Stelzer JE, Fitzsimons DP, Moss RL. Ablation of myosin-binding pro-tein-C accelerates force development in mouse myocardium. Biophys J. 2006;90:4119-4127. (Pubitemid 43846126)
16. Palmer BM, Noguchi T, Wang Y, Heim JR, Alpert NR, Burgon PG, Seid-man CE, Seidman JG, Maughan DW, LeWinter MM. Effect of cardiac myosin binding protein-C on mechanoenergetics in mouse myocardium. Circ Res. 2004;94:1615-1622. (Pubitemid 38856969)
17. Nyland LR, Palmer BM, Chen Z, Maughan DW, Seidman CE, Seid-man JG, Kreplak L, Vigoreaux JO. Cardiac myosin binding protein-C is essential for thick-filament stability and flexural rigidity. Biophys J. 2009;96:3273-3280.
18. Chen Y, Somji A, Yu X, Stelzer JE. Altered in vivo left ventricular torsion and principal strains in hypothyroid rats. Am J Physiol Heart Circ Physiol. 2010;299:H1577-H1587.
19. Stelzer JE, Larsson L, Fitzsimons DP, Moss RL. Activation dependence of stretch activation in mouse skinned myocardium: implications for ventricular function. J Gen Physiol. 2006;127:95-107. (Pubitemid 43177133)
20. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358:1370-1380.
21. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580-1589. (Pubitemid 38451712)
22. Pohlmann L, Kröger I, Vignier N, Schlossarek S, Krämer E, Coirault C, Sultan KR, El-Armouche A, Winegrad S, Eschenhagen T, Carrier L. Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ Res. 2007;101:928-938. (Pubitemid 350287180)
23. Cazorla O, Szilagyi S, Vignier N, Salazar G, Krämer E, Vassort G, Carrier L, Lacampagne A. Length and protein kinase A modulations of myo-cytes in cardiac myosin binding protein C-deficient mice. Cardiovasc Res. 2006;69:370-380. (Pubitemid 43098793)
24. Chen PP, Patel JR, Rybakova IN, Walker JW, Moss RL. Protein kinase A-induced myofilament desensitization to Ca (2+) as a result of phos-phorylation of cardiac myosin-binding protein C. J Gen Physiol. 2010;136:615-627.
25. Craig R, Offer G. The location of C-protein in rabbit skeletal muscle. Proc R Soc Lond B Biol Sci. 1976;192:451-461.
26. Bennett P, Craig R, Starr R, Offer G. The ultrastructural location of C-protein, X-protein and H-protein in rabbit muscle. J Muscle Res Cell Motil. 1986;7:550-567. (Pubitemid 17222611)
27. Pepe FA, Drucker B. The myosin filament. III. C-protein. J Mol Biol. 1975;99:609-617.
28. Palmer BM, Sadayappan S, Wang Y, Weith AE, Previs MJ, Bekyarova T, Irving TC, Robbins J, Maughan DW. Roles for cardiac MyBP-C in maintaining myofilament lattice rigidity and prolonging myosin cross-bridge lifetime. Biophys J. 2011;101:1661-1669.
29. Sadayappan S, Gulick J, Osinska H, Martin LA, Hahn HS, Dorn GW 2nd, Klevitsky R, Seidman CE, Seidman JG, Robbins J. Cardiac myo-sin-binding protein-C phosphorylation and cardiac function. Circ Res. 2005;97:1156-1163.
30. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaro-shinsky A, Zsebo KM, Dittrich H, Hajjar RJ; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304-313.
31. Szatkowski ML, Westfall MV, Gomez CA, Wahr PA, Michele DE, Del-loRusso C, Turner II, Hong KE, Albayya FP, Metzger JM. In vivo acceleration of heart relaxation performance by parvalbumin gene delivery. J Clin Invest. 2001;107:191-198. (Pubitemid 32096835)
32. Zahka K, Kalidas K, Simpson MA, Cross H, Keller BB, Galambos C, Gurtz K, Patton MA, Crosby AH. Homozygous mutation of MYBPC3 associated with severe infantile hypertrophic cardiomyopathy at high frequency among the Amish. Heart. 2008;94:1326-1330.
33. Lekanne Deprez RH, Muurling-Vlietman JJ, Hruda J, Baars MJ, Wijnaendts LC, Stolte-Dijkstra I, Alders M, van Hagen JM. Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene. J Med Genet. 2006;43:829-832. (Pubitemid 44654744)
34. Ortiz MF, Rodríguez-García MI, Hermida-Prieto M, Fernández X, Veira E, Barriales-Villa R, Castro-Beiras A, Monserrat L. A homozygous MYBPC3 gene mutation associated with a severe phenotype and a high risk of sudden death in a family with hypertrophic cardiomyopathy. Rev Esp Cardiol. 2009;62:572-575.
35. Rapti K, Chaanine AH, Hajjar RJ. Targeted gene therapy for the treatment of heart failure. Can J Cardiol. 2011;27:265-283.
36. Davis J, Westfall MV, Townsend D, Blankinship M, Herron TJ, Guerrero-Serna G, Wang W, Devaney E, Metzger JM. Designing heart performance by gene transfer. Physiol Rev. 2008;88:1567-1651.
37. Ly H, Kawase Y, Yoneyama R, Hajjar RJ. Gene therapy in the treatment of heart failure. Physiology (Bethesda). 2007;22:81-96.